Epidermolysis bullosa (EB) is a group of rare genetic skin disorders that cause the skin to blister and tear from minor friction or trauma. Even everyday activities like walking, being held, or rubbing against clothing can create painful wounds. The condition affects roughly 1 in every 24,000 live births, and because it results from inherited gene mutations, symptoms typically appear at birth or in early infancy.
EB ranges widely in severity. Some people experience mild blistering on their hands and feet, while others develop widespread wounds that affect internal organs and carry life-threatening complications. Understanding which type of EB someone has is essential for anticipating what lies ahead and how to manage it.
How EB Damages the Skin
Normal skin has layers that are held together by structural proteins, much like mortar holds bricks in a wall. In EB, mutations in the genes responsible for producing these proteins mean the layers don’t bond properly. When the skin experiences even light pressure or friction, the layers separate and fluid-filled blisters form. Where the separation occurs within the skin determines the type of EB and, largely, its severity.
This isn’t a problem that develops over time. The faulty gene is present from conception, which is why newborns with EB can arrive with blisters already formed from the pressures of delivery. The condition is lifelong because the underlying genetic defect is present in every skin cell the body produces.
The Four Main Types
Epidermolysis Bullosa Simplex (EBS)
EBS is the most common form, accounting for about 46% of all cases. Blistering occurs within the outermost layer of skin because the proteins that give structure to skin cells (keratin 5 and keratin 14) are defective. In most people with EBS, blisters tend to form on the hands and feet, often worsening in warm weather or with increased physical activity. EBS is usually the mildest form, and blisters generally heal without significant scarring.
Junctional Epidermolysis Bullosa (JEB)
JEB makes up roughly 19% of cases. The blistering occurs at the junction where the outer skin layer meets the deeper tissue beneath it. The proteins affected here, primarily laminin-332 and type XVII collagen, serve as anchors between these layers. JEB varies considerably: some subtypes are relatively mild, while the severe generalized form can cause widespread blistering from birth and carries serious complications. JEB has the lowest prevalence in the population relative to its incidence, which reflects the unfortunately high early mortality in severe cases.
Dystrophic Epidermolysis Bullosa (DEB)
DEB accounts for about 35% of cases. It results from mutations in a single gene that produces type VII collagen, the protein that forms tiny anchoring fibers connecting the skin layers to the tissue below. Because the separation occurs deeper in the skin, DEB blisters heal with significant scarring. Over years, repeated scarring on the hands can cause the fingers to fuse together, a complication called pseudosyndactyly. DEB can be inherited in a dominant pattern (one copy of the faulty gene from one parent) or a recessive pattern (one copy from each parent). The recessive form, called RDEB, is typically far more severe.
Kindler Epidermolysis Bullosa
Kindler EB is the rarest form, representing less than 1% of cases. Unlike the other types, blistering can occur at multiple levels within the skin, making it harder to classify by location alone. People with Kindler EB also develop increased sun sensitivity and progressive skin thinning over time.
Beyond the Skin
EB is often called a skin disease, but in moderate and severe forms it affects the entire body. The same structural proteins that hold skin together also line the mouth, esophagus, and other internal surfaces. Blistering and scarring in the esophagus can make swallowing painful and eventually narrow the passage, making it difficult to eat enough. Acid reflux is common and worsens the problem.
Dental enamel defects leave teeth vulnerable to rapid decay. Blistering in the mouth makes oral hygiene painful, compounding the issue. The eyes, urinary tract, kidneys, and musculoskeletal system can all be involved depending on the EB type and severity. Chronic wounds and inflammation also place enormous demands on the body’s nutritional reserves, and many people with severe EB struggle with anemia, poor growth, and delayed wound healing as a result.
Cancer Risk in Severe DEB
One of the most serious long-term risks is squamous cell carcinoma, a type of skin cancer that develops in areas of chronic wounding and scarring. For people with severe recessive DEB, this risk is strikingly high: roughly 7.5% develop squamous cell carcinoma by age 20, and over 90% by age 55. These cancers tend to be aggressive in EB patients, with a cumulative risk of death from this cancer reaching 57% by age 35. Regular skin surveillance is a critical part of care for anyone with RDEB.
How EB Is Diagnosed
EB is usually suspected when a newborn or infant develops blisters with no clear cause, or when there is a known family history. Confirming the diagnosis and identifying the specific subtype requires specialized testing.
Genetic testing is the cornerstone of diagnosis. It identifies the exact gene mutation responsible, which determines the EB type, predicts severity, and enables genetic counseling for the family. A technique called immunofluorescence mapping can also be performed on a small skin biopsy. This test uses fluorescent markers to show exactly which proteins are missing or reduced in the skin, providing a rapid initial diagnosis and helping guide which genes to test. Ideally, both genetic testing and immunofluorescence mapping are performed together for a complete picture.
For families with a known mutation, prenatal genetic testing is available and can identify whether a future child will be affected. This testing is technically possible for all EB subtypes, though it requires that the specific family mutation has already been identified.
Living With EB: Pain and Daily Care
Daily wound care is the defining challenge of life with EB. Blisters need to be lanced and drained carefully to prevent them from spreading, then covered with non-adherent dressings that won’t tear the fragile skin when removed. For someone with severe EB, bandage changes can take one to several hours each day and are often intensely painful.
Pain in EB is both acute and chronic. Fresh blisters and open wounds cause sharp, immediate pain, while long-standing wounds produce a deeper, burning sensation similar to neuropathic pain. Many people with severe EB require long-acting pain medications to maintain a baseline level of comfort, with additional short-acting options for wound care sessions. Cognitive behavioral therapy has shown benefit for managing the chronic pain component.
Nutrition plays a direct role in how well wounds heal. People with severe EB need significantly more calories and protein than average because their bodies are constantly repairing tissue. Esophageal scarring and mouth blisters make eating difficult, creating a cycle where the people who need the most nutrition have the hardest time getting it. Soft, calorie-dense foods, nutritional supplements, and prompt treatment of swallowing difficulties are all part of managing this.
Constipation is another frequent issue, worsened by pain medications and limited fluid intake. Keeping stools soft through hydration, dietary fiber, and stool softeners helps prevent painful complications in an already vulnerable area.
Treatment Options
There is no cure for EB, but the treatment landscape has shifted significantly in recent years. For most of EB’s history, care was limited to wound management and treating complications as they arose. That changed in 2023 with the first approved gene therapy.
Beremagene geperpavec, approved by the FDA in May 2023, is a topical gene therapy for dystrophic EB. It uses a modified, harmless virus to deliver working copies of the gene for type VII collagen directly to wound sites. When applied to a wound, the skin cells take up the gene and begin producing the missing protein, allowing the wound to form functional anchoring fibers and heal. It was the first gene therapy of any kind approved for a skin disease.
A second treatment, a topical gel containing birch bark extract, was approved by the FDA in December 2023 for wound healing in both junctional and dystrophic EB. It works by reducing inflammation, promoting the migration of skin cells into the wound, and providing some antimicrobial protection.
Beyond these newer options, the daily reality of EB management still revolves around meticulous wound care, pain control, nutritional support, physical therapy to maintain mobility (especially for hands affected by scarring), and regular monitoring for complications like esophageal narrowing, nutritional deficiencies, and skin cancer.